Safety and tolerability of non-neutralizing adrenomedullin antibody adrecizumab (HAM8101) in septic shock patients: the AdrenOSS-2 phase 2a biomarker-guided trialPierre‐François Laterre, Anne-Aurore Duchambon, Vincent Huberlant et al.|Intensive Care Medicine|2021Cited by 92